🔴 AIDX is trading 9.6% down today as investors digest new strategy and M&A plans

AIDX is trading at $0.55 (9.6% down) as investors react to the company's recently unveiled strategic roadmap and M&A objectives.

• The price movement follows a July 1 investor presentation detailing 20/20 Biolabs’ bolt-on acquisition strategy.
• The presentation outlined the reimbursement path for OneTest, the company's multi-cancer early detection product.
• No additional pre-market developments have been reported to account for the current downward trend.